


PRODUCT INFORMATION



Tozadenant

Item No. 28452

CAS Registry No.: 870070-55-6
Formal Name: 4-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide
MF: C₁₉H₂₆N₄O₄S
FW: 406.5
Purity: ≥98%
UV/Vis.: λ_{max}: 255, 284 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tozadenant is supplied as a crystalline solid. A stock solution may be made by dissolving the tozadenant in the solvent of choice, which should be purged with an inert gas. Tozadenant is soluble in the organic solvent dimethyl formamide (DMF) at a concentration of approximately 2 mg/ml.

Tozadenant is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, tozadenant should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Tozadenant has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Tozadenant is an adenosine A_{2A} receptor antagonist (K_is = 11.5 and 6 nM for the human and rhesus monkey receptors, respectively).¹ It increases the distance traveled and reduces contralateral asymmetry in the open field test in a rat model of Parkinson's disease induced by 6-OHDA (Item No. 25330) when administered at a dose of 30 mg/kg.² Tozadenant (150 mg/kg) reverses locomotor deficits and restores novel object-stimulated locomotion in a marmoset model of MPTP-induced Parkinson's disease.³

References

1. Barret, O., Hannestad, J., Alagille, D., *et al.* Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeys. *J. Nucl. Med.* **55**(10), 1712-1718 (2014).
2. Michel, A., Downey, P., Van Damme, X., *et al.* Behavioural assessment of the A_{2a}/NR2B combination in the unilateral 6-OHDA-lesioned rat model: A new method to examine the therapeutic potential of non-dopaminergic drugs. *PLoS One* **10**(8), e0135949 (2015).
3. Michel, A., Nicolas, J.M., Rose, S., *et al.* Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets. *PLoS One* **12**(8), e0182887 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/17/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM